Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B.

Antiviral therapy - 1 Jan 2014

Arends Pauline, van der Eijk Annemiek A, Sonneveld Milan J, Hansen Bettina E, Janssen Harry L A, Haagmans Bart L

Abstract excerpt

BACKGROUND: Several factors have been related to response to pegylated interferon (PEG-IFN) in chronic hepatitis B (CHB). The occurrence of anti-IFN antibodies is associated with non-response to PEG-IFN in chronic hepatitis C. This study investigated the association between anti-IFN antibodies and response to PEG-IFN in CHB. METHODS: Presence of anti-IFN antibodies was assessed at baseline and at 3 and 6 months...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Interferons

Share to Treatment Failure

Share to Treatment Outcome

Share to Viral Load

Source

Identifiers

PMID: 24296674
DOI: 10.3851/IMP2711

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B.PMID 24296674Read ↗

Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFNSemantic proximity Read ↗

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.Semantic proximity Read ↗

Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers.Semantic proximity Read ↗

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.Semantic proximity Read ↗

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.Semantic proximity Read ↗

Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.Semantic proximity Read ↗

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.Semantic proximity Read ↗

Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment.Semantic proximity Read ↗

Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.Semantic proximity Read ↗

Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.Semantic proximity Read ↗

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.Semantic proximity Read ↗

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.